OTC · Biotechnology

CStone Pharmaceuticals (CSPHF) Stock

$0.71 +0.00% OTC: CSPHF Healthcare

CStone Pharmaceuticals is a biopharmaceutical firm dedicated to discovering, developing, and marketing innovative immuno-oncology and precision medicine therapies. Their primary objective is to fulfill critical medical requirements for cancer patients, both within China and across global markets.

Valuation

MetricValue
Price$0.71
Market Cap$1.14B
P/E Ratio-19.48
P/B Ratio9.70
P/S Ratio26.71
EPS (TTM)$-0.31
52-Week High$1.01
52-Week Low$0.60
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-64.78%
ROA-22.22%
ROCE-34.65%
Gross Margin39.88%
Operating Margin-120.09%
Net Margin-123.30%
Debt/Equity0.57
Current Ratio2.18

Annual Financials (USD)

Metric20212022202320242025
Revenue$244.0M$481.0M$464.0M$407.0M$263.0M
Operating Profit$-1.8B$-912.0M$-580.0M$-92.0M$-421.0M
Net Profit$-1.9B$-903.0M$-367.0M$-91.0M$-426.0M
EPS$-1.65$-0.77$-0.29$-0.07$-0.31
Op Margin-750.6%-189.5%-125.0%-22.5%-160.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$2.3B$1.6B$1.7B$1.4B$1.4B
Total Liabilities$1.1B$1.2B$1.2B$1.0B$742.0M
Cash$743.0M$559.0M$997.0M$388.0M$754.0M
Borrowings$174.0M$286.0M$363.0M$356.0M$349.0M

Latest News

CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand PR Newswire · Jun 25, 2026 CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights PR Newswire · Jun 11, 2026 ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept PR Newswire · Jun 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-1.5B$-612.0M$-589.0M$-343.0M$-328.0M
Investing Cash Flow$-976.0M$263.0M$555.0M$-248.0M$134.0M
Financing Cash Flow$-14.0M$-12.0M$-45.0M$-12.0M$-119.0M
Net Cash Flow$-2.3B$-184.0M$438.0M$-609.0M$366.0M
Free Cash Flow$-1.6B$-714.0M$-654.0M$-343.0M$-328.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.14
EV / EBITDA-23.07
FCF Yield-5.40%
Quick Ratio1.95
Interest Coverage-32.07
Return 1Y13.60%
Return 3Y51.06%
Return 5Y—

Ownership

Insiders Held19.79%
Institutions Held15.68%
Institutions Float Held19.55%
Institutional HolderSharesReport Date
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund16,331,5002026-04-30
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard Emerging Markets Stock Index Fd15,500,0002026-04-30
iShares, Inc.-iShares Core MSCI Emerging Markets ETF14,344,5002026-05-31
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard FTSE All-World ex-US Small-Cap 4,152,0002026-04-30
Invesco Exch-Trd Fd. TRT II-Invesco Dorsey Wright Emerging Markets Mom3,075,4032026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ASCLFAscletis Pharma Inc. $1.42 +0.00% -20.87 $1.49B 0.00%
CHIZFChina Traditional Chinese Medicine Holdings Co. Limited $0.16 +0.00% -19.84 $821.34M 6.25%
CSBTFKuros Biosciences AG $25.57 +0.00% 478.87 $1.01B 0.00%
MEOBFMesoblast Limited $1.70 +0.00% -22.15 $2.20B 0.00%
NURPFNeuren Pharmaceuticals Limited $13.46 +0.00% 68.94 $1.71B 0.00%

About CStone Pharmaceuticals

CStone Pharmaceuticals is a biopharmaceutical firm dedicated to discovering, developing, and marketing innovative immuno-oncology and precision medicine therapies. Their primary objective is to fulfill critical medical requirements for cancer patients, both within China and across global markets. The company currently provides several key therapeutic agents. These include Sugemalimab, a monoclonal antibody specifically targeting programmed death-ligand 1 (PD-L1); GAVRETO, an RET inhibitor prescribed for advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor used in adults with unresectable or metastatic gastrointestinal stromal tumors that carry a PDGFRA exon 18 mutation. CStone's robust product pipeline features promising candidates such as Nofazinlimab, a PD-1 antibody aimed at treating hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor developed for adults experiencing relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor also indicated for hepatocellular carcinoma. Further augmenting its development portfolio are various compounds including CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500, all targeting solid tumors, alongside CS5001, which addresses both solid tumors and hematologic malignancies. Established in 2015, CStone Pharmaceuticals maintains its headquarters in Shanghai, China.

CStone Pharmaceuticals is headquartered in CN.

CStone Pharmaceuticals (CSPHF) stock trades at $0.71 with a market capitalization of $1.14B. The stock is valued at a price-to-earnings (P/E) ratio of -19.48, price-to-book of 9.70, price-to-sales of 26.71. Over the past 52 weeks the stock has ranged between $0.60 and $1.01, and currently trades 29.7% below its 52-week high.

On profitability, CStone Pharmaceuticals generates a return on equity (ROE) of -64.78%, return on capital employed of -34.65%, an operating margin of -120.09%, a net profit margin of -123.30%.

Official website: www.cstonepharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides